Detalhe da pesquisa
1.
XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies.
Mol Cancer Ther
; 23(4): 421-435, 2024 Apr 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38030380
2.
XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, demonstrates tumor-growth inhibition and tumor-selective pharmacodynamics in mouse models of cancer.
J Immunother Cancer
; 11(12)2023 12 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38164757
3.
Differentiated agonistic antibody targeting CD137 eradicates large tumors without hepatotoxicity.
JCI Insight
; 5(5)2020 03 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32161196
4.
Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models.
Clin Cancer Res
; 23(19): 5869-5880, 2017 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28679778
5.
The immunocytokine NHS-IL12 as a potential cancer therapeutic.
Oncotarget
; 5(7): 1869-84, 2014 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24681847